EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...
The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...
NanoViricides has signed a broad Memorandum of Understanding Agreement (MoU) with TheraCour encompassing all antiviral drugs developments on September 23, 2024, an important step that provides the ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
Christine L. Larsen, MD, is an ophthalmologist practicing at Minnesota Eye Consultants where she serves as medical director for the four ancillary surgery centers in the practice. Conjunctivitis ...
The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...
Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall S.A. has licensed the rights to develop and ...
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback